REFLECTIONS OF A PHARMACIST, ACADEMIC AND RESEARCHER IN A PIVOTAL YEAR OF CHANGE FOR THE PHARMACY PROFESSION
Dr Kate Wang, Senior Lecturer in Pharmacy, RMIT University &
Adjunct Senior Lecturer, University of Western Australia
PEOPLE IN HEALTH CARE
Filmed in Melbourne, Victoria | December 2024
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
With Australia’s ageing population projected to reach 21-23% of those over 65 by 2060, the need for effective medication management is crucial. Older adults often face multiple chronic conditions and take multiple medications, making pharmacists essential as medication experts.
Pharmacists are the most accessible healthcare professionals in Australia, allowing for regular patient interactions. This consistent contact enables them to provide ongoing monitoring and health management, highlighting the importance of expanding their scope of practice. Dr. Wang emphasises the trialing of structured prescribing for conditions like uncomplicated urinary tract infections and oral contraceptives, where timely access is vital.
Attending the PSA24 conference hosted by the Pharmaceutical Society of Australia in Sydney, she noted the collaborative efforts among healthcare professionals to address changes in scope of practice. The process requires thorough review and piloting, with a commitment to patient centred care. As the field evolves, pharmacists must adapt to new treatments and emerging health challenges, continuously striving to make a positive impact on individuals and the broader community.
-
New bar for cosmetic plastic surgeon accreditation
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
-
Belonging in a medical device company
Edith de Boer is the HR Director for Zimmer Biomet in Australia and New Zealand. Her career originally was in telecommunications and consulting in Europe. After leaving The Netherlands, Edith worked into the Australian medical research industry, before moving into a human resources role at Zimmer Biomet. Edith spoke to Australian Health Journal about her role and the organisation.
-
25 years of non-indexation of nuclear medicine impeding access & affordability
The President of the Australasian Association of Nuclear Medicine Specialists (AANMS), Associate Professor Sze Ting Lee spoke with Australian Health Journal about the following:
Usual levels of nuclear medicine services in Australia each year
Current levels of nuclear medicine services in Australia
How changing demographics in people moving to regional areas has impacted access to nuclear medicine services
The nuclear medicine workforce including trainees
The key recommendations from the pre-budget submissionIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
